ALZPROTECT Announces FDA Clearance of IND for AZP2006 (Ezeprogind®) in Progressive Supranuclear Palsy (PSP)
Lille, France — May 19th 2026 — Alzprotect today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for AZP2006 (Ezeprogind®) for the treatment of Progressive Supranuclear Palsy (PSP). FDA clearance permits the Company to begin clinical development of AZP2006 in the United States.
“FDA IND clearance is a pivotal step in our PSP program,” said Philippe Verwaerde, PhD, President & Chief science Officer “We can now expand our clinical efforts in the U.S. to evaluate AZP2006’s potential to address PSP, a severe neurodegenerative disease with no approved disease-modifying therapies.”
Dr. Artin Karapet, Chief Medical Officer, commented: “The FDA’s clearance of our IND for AZP2006 is a pivotal milestone, aligning U.S. and European regulatory pathways and enabling the initiation of rigorous clinical trials in the United States for patients living with PSP.”
Upcoming U.S. Clinical Study
This IND clearance enables U.S. clinical development and supports Alzprotect’s planned participation in the NIH/NIA-funded Progressive Supranuclear Palsy Trial Platform (PTP). AZP2006 was selected as one of the first candidates for evaluation in the PTP, reinforcing the relevance of Alzprotect’s lysosomal dysfunction approach in PSP.